1. Home
  2. WFRD vs DFTX Comparison

WFRD vs DFTX Comparison

Compare WFRD & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weatherford International plc

WFRD

Weatherford International plc

HOLD

Current Price

$94.64

Market Cap

6.6B

Sector

Industrials

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$42.31

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WFRD
DFTX
Founded
1941
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.9B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
WFRD
DFTX
Price
$94.64
$42.31
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$103.22
$38.50
AVG Volume (30 Days)
1.2M
2.1M
Earning Date
04-21-2026
05-04-2026
Dividend Yield
1.03%
N/A
EPS Growth
N/A
N/A
EPS
2.04
N/A
Revenue
$4,331,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.22
N/A
P/E Ratio
$45.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.74
$14.62
52 Week High
$113.15
$49.70

Technical Indicators

Market Signals
Indicator
WFRD
DFTX
Relative Strength Index (RSI) 61.01 49.67
Support Level $82.64 $40.29
Resistance Level $97.79 $49.13
Average True Range (ATR) 3.27 2.71
MACD 1.11 -0.50
Stochastic Oscillator 98.13 22.69

Price Performance

Historical Comparison
WFRD
DFTX

About WFRD Weatherford International plc

Weatherford provides oilfield services and equipment to national, integrated, public, and private oil and gas operators. It operates across multiple upstream markets, including offshore, the rest of the world onshore, and US onshore, where Weatherford has limited exposure. The Middle East, North Africa, and Asia account for over 25% of sales. Weatherford also offers manufacturing, research, and training services. Performance is reported through three segments: drilling and evaluation, well construction and completions, and production and intervention.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: